Fundamental Analysis of THERATECHNOLOGIES INC(NASDAQ:THTX) stock

Fundamental Rating

THTX gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 588 industry peers in the Biotechnology industry. THTX has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, THTX is valued expensive at the moment.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year THTX has reported negative net income.

THTX had a negative operating cash flow in the past year.

THTX had negative earnings in each of the past 5 years.

In the past 5 years THTX always reported negative operating cash flow.

1.2 Ratios

THTX has a Return On Assets of -24.96%. This is in the better half of the industry: THTX outperforms 77.40% of its industry peers.

		Industry Rank	Sector Rank
ROA	-24.96%
ROE	N/A
ROIC	N/A

ROA(3y)-36.02%

ROA(5y)-28.27%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Gross Margin of THTX (74.10%) is better than 85.27% of its industry peers.

THTX's Gross Margin has improved in the last couple of years.

The Profit Margin and Operating Margin are not available for THTX so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	74.1%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y9.49%

GM growth 5Y1.53%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

THTX does not have a ROIC to compare to the WACC, probably because it is not profitable.

THTX has more shares outstanding than it did 1 year ago.

The number of shares outstanding for THTX has been reduced compared to 5 years ago.

The debt/assets ratio for THTX is higher compared to a year ago.

2.2 Solvency

THTX has an Altman-Z score of -6.96. This is a bad value and indicates that THTX is not financially healthy and even has some risk of bankruptcy.

THTX has a worse Altman-Z score (-6.96) than 69.52% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Altman-Z	-6.96

ROIC/WACCN/A

WACC10.08%

2.3 Liquidity

A Current Ratio of 1.15 indicates that THTX should not have too much problems paying its short term obligations.

Looking at the Current ratio, with a value of 1.15, THTX is doing worse than 86.99% of the companies in the same industry.

THTX has a Quick Ratio of 1.03. This is a normal value and indicates that THTX is financially healthy and should not expect problems in meeting its short term obligations.

With a Quick ratio value of 1.03, THTX is not doing good in the industry: 86.99% of the companies in the same industry are doing better.

		Industry Rank	Sector Rank
Current Ratio	1.15
Quick Ratio	1.03

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 70.67% over the past year.

THTX shows a decrease in Revenue. In the last year, the revenue decreased by -4.06%.

THTX shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 12.58% yearly.

EPS 1Y (TTM)70.67%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q77.27%

Revenue 1Y (TTM)-4.06%

Revenue growth 3Y7.37%

Revenue growth 5Y12.58%

Revenue growth Q2Q-18.39%

3.2 Future

The Earnings Per Share is expected to grow by 21.44% on average over the next years. This is a very strong growth

The Revenue is expected to grow by 18.41% on average over the next years. This is quite good.

EPS Next Y59.67%

EPS Next 2Y22.08%

EPS Next 3Y31.29%

EPS Next 5Y21.44%

Revenue Next Year6.96%

Revenue Next 2Y7.56%

Revenue Next 3Y10.7%

Revenue Next 5Y18.41%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for THTX. In the last year negative earnings were reported.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for THTX. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as THTX's earnings are expected to grow with 31.29% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y22.08%

EPS Next 3Y31.29%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for THTX!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

THERATECHNOLOGIES INC

NASDAQ:THTX (4/26/2024, 7:19:32 PM)

1.3

0 (0%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap31.46M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-24.96%
ROE	N/A
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	74.1%
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover1.08

Health

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	1.15
Quick Ratio	1.03
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)70.67%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next Y59.67%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)-4.06%

Revenue growth 3Y7.37%

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

THERATECHNOLOGIES INC (THTX)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens